Skip to main content

Table 6 Differences in laboratory tests, inflammation-based prognostic scores, and nutrition index according to Clavien-Dindo gradesa

From: Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy

  CD0 group (n = 61) CD1/2 group (n = 44) CD3/4 group (n = 10) P Value
Baseline
     HB (g/L) 129 (66–155) 121 (64–170) 112 (72–159) 0.284
     WBC (×109/L) 5.9 (3.6–13.9) 6.4 (3.6–14.2) 8.1 (3.9–10.2) 0.109
     NEU (×109/L) 3.6 (2.2–10.9) 3.9 (2.0–11.7) 4.8 (1.4–7.7) 0.136
     LYM (×109/L) 1.7 (0.7–3.1) 1.8 (0.6–3.0) 2.0 (1.4–2.4) 0.238
     PLT (×109/L) 298.0 (96.0–639.0) 295.0 (141.0–599.0) 301.5 (166.0–438.0) 0.784
     ALB (g/L) 42.0 (35.0–49.0) 41.0 (28.0–47.0) 39.0 (25.0–48.0) 0.631
     ALT (U/L) 14.0 (5.0–75.0) 14.5 (5.0–58.0) 13.0 (7.0–59.0) 0.888
     AST (U/L) 17.0 (10.0–56.0) 15.0 (8.0–73.0) 19.5 (10.0–37.0) 0.473
     ALP (U/L) 56.0 (24.0–109.0) 59.5 (25.0–123.0) 71.5 (31.0–99.0) 0.137
     Scr (mg/dL) 0.82 (0.48–1.20) 0.86 (0.53–1.28) 0.81 (0.68–1.59) 0.593
     aPTT (second) 29.8 (23.0–37.2) 29.6 (24.9–38.6) 28.6 (24.9–33.1) 0.315
     PT (second) 10.9 (9.3–12.8) 11.0 (9.0–13.1) 11.1 (9.5–12.7) 0.765
     INR 0.96 (0.82–1.12) 0.97 (0.79–1.16) 0.98 (0.84–1.11) 0.883
     PNI 50.2 (40.4–61.8) 50.6 (34.2–60.0) 49.7 (33.0–60.2) 0.954
     NLR 2.5 (0.7–6.6) 2.2 (1.0–9.5) 2.4 (0.7–7.8) 0.805
     PLR 181.9 (67.6–557.7) 179.1 (73.8–487.0) 171.1 (78.3–256.9) 0.683
Preoperative
     HB (g/L) 116 (86–152) 115 (76–160) 117 (91–125) 0.810
     WBC (×109/L) 4.7 (2.3–11.7) 4.7 (2.7–11.9) 5.8 (3.0–9.7) 0.598
     NEU (×109/L) 2.7 (0.7–8.8) 2.6 (1.2–9.1) 3.0 (1.5–7.8) 0.755
     LYM (×109/L) 1.5 (0.5–3.4) 1.6 (0.4–2.7) 1.3 (0.6–2.9) 0.835
     PLT (×109/L) 218.0 (73.0–398.0) 202.0 (91.0–583.0) 216.5 (167.0–276.0) 0.861
     ALB (g/L) 40.0 (27.0–48.0) 39.5 (26.0–52.0) 39.0 (32.0–41.0) 0.541
     ALT (U/L) 17.0 (6.0–72.0) 14.0 (6.0–52.0) 15.5 (11.0–43.0) 0.431
     AST (U/L) 20.0 (12.0–75.0) 19.0 (11.0–42.0) 19.0 (12.0–42.0) 0.671
     ALP (U/L) 61.5 (21.0–142.0) 59.5 (25.0–106.0) 63.5 (35.0–163.0) 0.887
     Scr (mg/dL) 0.78 (0.43–1.39) 0.78 (0.38–1.55) 0.75 (0.63–1.34) 0.874
     aPTT (second) 29.9 (24.2–41.5) 29.7 (20.7–37.5) 31.0 (26.1–34.6) 0.979
     PT (second) 10.5 (9.4–13.1) 10.9 (9.4–13.4) 10.5 (9.6–11.7) 0.196
     INR 0.93 (0.83–1.15) 0.97 (0.83–1.18) 0.94 (0.85–1.01) 0.147
     CRPb (mg/L) 1.1 (0.3–51.1) 1.3 (0.4–68.6) 1.8 (0.5–13.9) 0.502
     PNI 46.8 (30.5–59.9) 46.0 (33.2–62.1) 45.4 (37.2–54.3) 0.801
     NLR 1.7 (0.6–9.6) 1.9 (0.6–9.7) 2.0 (0.8–10.1) 0.811
     PLR 134.6 (38.2–574.1) 123.4 (44.7–640.7) 148.3 (66.1–392.1) 0.714
     GPSb,c     0.804
          Score 0 43 (81.1) 30 (76.9) 7 (87.5)  
          Score 1 8 (15.1) 6 (15.4) 0 (0.0)  
          Score 2 2 (3.8) 3 (7.7) 1 (12.5)  
     PIb,c     0.572
          Score 0 49 (92.5) 35 (89.7) 7 (87.5)  
          Score 1 4 (7.5) 4 (10.3) 1 (12.5)  
  1. ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; HB, hemoglobin; INR, international normalized ratio; LYM, lymphocyte count; NEU, neutrophil count; NLR, neutrophil–lymphocyte ratio; PI, Prognostic Index; PLR, platelet–lymphocyte ratio; PLT, platelet count; PNI, prognostic nutritional index; PT, prothrombin; Scr, serum creatinine; WBC, white blood cell count
  2. aData are presented as median (range) unless indicated otherwise
  3. bData retrieved from 100 patients, including 53 patients in CD0 group, 39 patients in CD1/2 group, and 8 patients in CD3/4 group
  4. cData are presented as number (percentage)